Escin inhibits type i allergic dermatitis in a novel porcine model

International Archives of Allergy and Immunology

Volumn 161, Issue 1, 2013, Pages 44-52

  Sipos, Wolfgang ^a   Reutterer, Benjamin ^b   Frank, Maria ^b   Unger, Hermann ^a   Grassauer, Andreas ^b   Prieschl Grassauer, Eva ^b   Doerfler, Petra ^b  

^a UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^b Marinomed Biotechnologie GmbH   (Austria)

Author keywords

Allergy; Compound 48 80; Escin; Glucocorticoid receptor; Pig; Skin prick test; Type I hypersensitivity

Indexed keywords

COMPOUND 48-80; ESCIN; HISTAMINE; ANTIALLERGIC AGENT; GLUCOCORTICOID RECEPTOR ALPHA;

ALLERGIC REACTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLS; CONTROLLED STUDY; DRUG EFFICACY; ERYTHEMA; MAST CELL; NONHUMAN; PRICK TEST; PRIORITY JOURNAL; SKIN ALLERGY; URTICARIA; ANIMAL CELL; DISEASE EXACERBATION; DOSE RESPONSE; FEMALE; IN VITRO STUDY; MALE; MAST CELL DEGRANULATION; MOUSE; PORCINE MODEL; PROTEIN PHOSPHORYLATION; SKIN SWELLING;

ANIMALS; ANTI-ALLERGIC AGENTS; DERMATITIS, ATOPIC; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; ESCIN; FEMALE; HISTAMINE; MALE; P-METHOXY-N-METHYLPHENETHYLAMINE; SKIN TESTS; SWINE;

EID: 84871208112     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000343289     Document Type: Article

References (46)

1. Devereux G: The increase in the prevalence of asthma and allergy: food for thought. Nat Rev Immunol 2006; 6:869-874. (Pubitemid 44631655)
2. Platts-Mills TA, Woodfolk JA: Allergens and their role in the allergic immune response. Immunol Rev 2011; 242: 51-68.
3. Baumruker T, Prieschl E: Mast cells and their activation-from the molecular mechanism to clinical relevance. Mod Asp Immunobiol 2001; 1:259-262.
4. Bloemen K, Verstraelen S, Van Den HR, Witters H, Nelissen I, Schoeters G: The allergic cascade: review of the most important molecules in the asthmatic lung. Immunol Lett 2007; 113: 6-18. (Pubitemid 47464616)
5. Galli SJ, Tsai M, Piliponsky AM: The development of allergic inflammation Nature 2008; 454:445-454.
6. Marshall JS: Mastcell responses to pathogens. Nat Rev Immunol 2004; 4:787-799.
7. Schacke H, Docke WD, Asadullah K: Mechanisms involved in the side effects of gluco-corticoids. Pharmacol Ther 2002; 96: 23-43. (Pubitemid 35346616)
8. Baroody FM, Naclerio RM: Antiallergic effects of H1-receptor antagonists. Allergy 2000; 55(suppl 64):17-27.
9. Rizzo MC, Sole D: Inhaled corticosteroids in the treatment of respiratory allergy: safety vs. efficacy. J Pediatr (Rio J) 2006; 82:S198-S205. (Pubitemid 44974673)
10. Adcock IM, Barnes PJ: Molecular mechanisms of corticosteroid resistance. Chest 2008; 134: 394-401.
11. Lindner I, Meier C, Url A, Unger H, Grassauer A, Prieschl-Grassauer E, et al: Betaes-cin has potent anti-allergic efficacy and reduces allergic airway inflammation. BMC Immunol 2010; 11: 24.
12. Guillaume M, Padioleau F: Veinotonic effect, vascular protection, antiinflammatory and free radical scavenging properties of horse chestnut extract. Arzneimittelforschung 1994; 44: 25-35. (Pubitemid 24036875)
13. Sirtori CR: Aescin: pharmacology, pharma-cokinetics and therapeutic profile. Pharmacol Res 2001; 44: 183-193. (Pubitemid 32889461)
14. Matsuda H, Li Y, Murakami T, Ninomiya K, Araki N, Yoshikawa M, et al: Antiinflammatory effects of escins Ia, Ib, IIa, and IIb from horse chestnut, the seeds of Aesculus hippo-castanum L. Bioorg Med Chem Lett 1997; 7: 1611-1616. (Pubitemid 27321471)
15. Matsuda H, Li Y, Murakami T, Ninomiya K, Yamahara J, Yoshikawa M: Effects of escins Ia, Ib, IIa, and IIb from horse chestnut, the seeds of Aesculus hippocastanum L., on acute inflammation in animals. Biol Pharm Bull 1997; 20:1092-1095. (Pubitemid 27497995)
16. Wang T, Fu F, Zhang L, Han B, Zhu M, Zhang X: Effects of escin on acute inf lamma-tion and the immune system in mice. Pharmacol Rep 2009; 61:697-704.
17. Wei F, Ma LY, Jin WT, Ma SC, Han GZ, Khan IA, Lin RC: Antiinflammatory triterpenoid saponins from the seeds of Aesculus chinen-sis. Chem Pharm Bull 2004; 52:1246-1248. (Pubitemid 41327523)
18. Xie Q, Zong X, Ge B, Wang S, Ji J, Ye Y, et al: Pilot postoperative ileus study of escin in cancer patients after colorectal surgery. World J Surg 2009; 33: 348-354.
19. Carrasco OF, Vidrio H: Endothelium protec-tant and contractile effects of the antivari-cose principle escin in rat aorta. Vascul Pharmacol 2007; 47:68-73. (Pubitemid 46818137)
20. Fu F, Hou Y, Jiang W, Wang R, Liu K: Escin: inhibiting inflammation and promoting gastrointestinal transit to attenuate formation of postoperative adhesions. World J Surg 2005; 29:1614-1620. (Pubitemid 41779863)
21. Ottillinger B, Greeske K: Rational therapy of chronic venous insufficiency-chances and limits of the therapeutic use of horse-chestnut seeds extract. BMC Cardiovasc Disord 2001; 1: 5.
22. Wetzel D, Menke W, Dieter R, Smasal V, Giannetti B, Bulitta M: Escin/diethylammo-nium salicylate/heparin combination gels for the topical treatment of acute impact injuries: a randomised, double blind, placebo controlled, multicentRestudy. Br J Sports Med 2002; 36: 183-188. (Pubitemid 34651936)
23. Tan SM, Li F, Rajendran P, Kumar AP, Hui KM, Sethi G: Identification of beta-escin as a novel inhibitor of signal transducer and activator of transcription 3/Janusactivated kinase 2 signaling pathway that suppresses proliferation and induces apoptosis in human hepatocellular carcinoma cells. J Pharmacol Exp Ther 2010; 334:285-293.
24. Harikumar KB, Sung B, Pandey MK, Guha S, Krishnan S, Aggarwal BB: Escin, a penta-cyclic triterpene, chemosensitizes human tumor cells through inhibition of NF-kap-paB signaling pathway. Mol Pharmacol 2010; 77:818-827.
25. Ming ZJ, Hu Y, Qiu YH, Cao L, Zhang XG: Synergistic effects of beta-aescin and 5-fluo-rouracil in human hepatocellular carcinoma SMMC-7721 cells. Phytomedicine 2010; 17: 575-580.
26. Zhang Z, Gao J, Cai X, Zhao Y, Wang Y, Lu W, et al: Escin sodium induces apoptosis of human acute leukemia Jurkat T cells. Phytother Res 2011; 25:1747-1755.
27. Patlolla JM, Raju J, Swamy MV, Rao CV: Beta-escin inhibits colonic aberrant crypt foci formation in rats and regulates the cell cycle growth by inducing p21(waf1/cip1) in colon cancer cells. Mol Cancer Ther 2006; 5:1459-1466. (Pubitemid 44070482)
28. Wang YW, Wang SJ, Zhou YN, Pan SH, Sun B: Escin augments the efficacy of gemcitabi-ne through down-regulation of nuclear fac-tor-kappaB and nuclear factor-kappaB-reg-ulated gene products in pancreatic cancer both in vitro and in vivo. J Cancer Res Clin Oncol 2012; 138: 785-797.
29. Meyer W, Schwarz R, Neurand K: The skin of domestic mammals as a model for the human skin, with special reference to the domestic pig. Curr Probl Dermatol 1978; 7: 39-52.
30. Vana G, Meingassner JG: Morphologic and immunohistochemical features of experimentally induced allergic contact dermatitis in Gottingen minipigs. Vet Pathol 2000; 37: 565-580.
31. Liu L, Wu X, Wu D, Wang Y, Li P, Sun Y, et al: A liquid chromatography-tandem mass spec-trometry method for the simultaneous quantification of escin Ia and escin Ib in human plasma: application to a pharmacokinetic study after intravenous administration. Biomed Chromatogr 2010; 24: 1309-1315.
32. Li B, Abliz Z, Fu G, Tang M, Yu S: Characteristic fragmentation behavior of some gluc-uronide-type triterpenoid saponins using electrospray ionization tandem mass spec-trometry. Rapid Commun Mass Spectrom 2005; 19: 381-390. (Pubitemid 40203855)
33. Henkel G, Weiss DL, McCoy R, Deloughery T, Tara D, Brown MA: A DNase I-hypersen-sitive site in the second intron of the murine IL-4 gene defines a mast cell-specific enhancer. J Immunol 1992; 149:3239-3246.
34. Lagunoff D, Martin T W, Read G: Agentst hat release histamine from mast cells. Annu Rev Pharmacol Toxicol 1983; 23: 331-351. (Pubitemid 13079379)
35. Vodicka P, Smetana Jr K, Dvorankova B, Emerick T, Xu YZ, Ourednik J, et al: The miniature pig as an animal model in bio-medical research. Ann NY Acad Sci 2005; 1049: 161-171. (Pubitemid 40967583)
36. Devillier P, Bousquet J: Inhibition of the his-tamine-induced weal and flare response: a valid surrogate measure for antihistamine clinica l eff icacy? Clin Exp Allergy 2007; 37: 400-414. (Pubitemid 46393241)
37. Greeske K, Pohlmann BK: Horse chestnut seed extract-an effective therapy principle in general practice: drug therapy of chronic venous insufficiency. Fortschr Med 1996; 114: 196-200.
38. Oschmann R, Biber A, Lang F, Stumpf H, Kunz K: Pharmaokinetics of beta-escin after administration of various Aesculus extract containing formulations. Pharmazie 1996; 51: 577-581.
39. Jiang N, Xin W, Wang T, Zhang L, Fan H, Du Y, et al: Protective effect of aescin from the seeds of Aesculus hippocastanum on liver injury induced by endotoxin in mice. Phytomedicine 2011; 18: 1276-1284.
40. Xin W, Zhang L, Fan H, Jiang N, Wang T, Fu F: Escin attenuates acute lung injury induced by endotoxin in mice. Eur J Pharm Sci 2011; 42:73-80.
41. Xin W, Zhang L, Sun F, Jiang N, Fan H, Wang T, et al: Escin exerts synergistic anti-inflammatory effects with low doses of glucocorti-coids in vivo and in vitro. Phytomedicine 2011; 18: 272-277.
42. Wang Z, Frederick J, Garabedian MJ: Deciphering the phosphorylation 'code' of the glucocorticoid receptor in vivo. J Biol Chem 2002; 277: 26573-26580. (Pubitemid 34967155)
43. De Bosscher K, Beck IM, Haegeman G: Classic glucocorticoids versus non-steroidal glu-cocorticoid receptor modulators: survival of the fittest regulator of the immune system? Brain Behav Immun 2010; 24:1035-1042.
44. Adcock IM, Chou PC, Durham A, Ford P: Overcoming steroid unresponsiveness in airways disease. Biochem Soc Trans 2009; 37: 824-829.
45. Gross KL, Lu NZ, Cidlowski JA: Molecular mechanisms regulating glucocorticoid sensitivity and resistance. Mol Cell Endocrinol 2009; 300:7-16.
46. Barnes PJ: Mechanisms and resistance in glucocorticoid control of inflammation. J Steroid Biochem Mol Biol 2010; 120:76-85.